



FOURTH-QUARTER AND FULL-YEAR 2023 RESULTS

TOTAL COMPANY

WORLDWIDE SALES

Q4 **\$10.2B** **+11.0%**¹

FULL YEAR **\$40.1B** **+11.6%**²

ORGANIC* SALES GROWTH FOR UNDERLYING BASE BUSINESS**

EXCEEDED MIDPOINT OF ORIGINAL GUIDANCE RANGE ISSUED IN JANUARY 2023

\$4.44³ ADJUSTED DILUTED EPS

BUSINESS HIGHLIGHTS

ADVANCES IN ELECTROPHYSIOLOGY

- ▶ Conducted first-in-human procedures using Abbott's new Volt™ Pulsed Field Ablation (PFA) System to treat patients with heart rhythm disorders such as atrial fibrillation (AFib).
- ▶ These procedures were part of Abbott's Volt CE Mark clinical study.



INNOVATION IN DIABETES CARE

- ▶ Abbott's first automated insulin delivery (AID) system integration in the U.S. features the new FreeStyle Libre®*** 2 Plus sensor and Tandem Diabetes Care's t:slim X2™⁶ insulin pump.
- ▶ System helps predict and prevent high and low blood sugar.



HELPING LABS BOOST PERFORMANCE

- ▶ FDA approval for new clinical lab automation system, GLP systems Track™.
- ▶ System will help laboratories optimize performance and safety to better meet the growing demand for diagnostic testing.



KEY BUSINESS UNITS⁴

ORGANIC* FOURTH-QUARTER 2023 SALES GROWTH FOR UNDERLYING BASE BUSINESS**



15.4%
MEDICAL DEVICES



2.2%
DIAGNOSTICS



13.9%
NUTRITION



8.8%
ESTABLISHED PHARMACEUTICALS

FULL-YEAR 2024 GUIDANCE

8.0% to 10.0% | **\$4.50 to \$4.70**⁵

RANGE FOR ORGANIC SALES GROWTH EXCLUDING COVID-19 TESTING-RELATED SALES

ADJUSTED DILUTED EPS

*Organic sales growth excludes impact of foreign exchange, impact of exiting the pediatric nutrition business in China, and the impact of the acquisition of Cardiovascular Systems, Inc. For full financial data and reconciliation of non-GAAP measures, please see our press release dated Jan. 24, 2024, available at www.abbottinvestor.com.

**Excludes the impact of COVID-19 testing sales.

***Find important safety information about the FreeStyle Libre portfolio: www.freestylelibre.us/safety-information.

1. On a GAAP basis, fourth-quarter 2023 Abbott sales increased 1.5%. 2. On a GAAP basis, full-year 2023 Abbott sales decreased 8.1%. 3. Full-year 2023 GAAP diluted EPS was \$3.26. 4. On a GAAP basis, fourth-quarter 2023 Medical Devices sales increased 17.5%, Nutrition sales increased 12.2%, Diagnostics sales decreased 22.7% and Established Pharmaceuticals sales increased 0.5%. 5. Abbott projects full-year 2024 diluted earnings per share under GAAP of \$3.20 to \$3.40. Abbott forecasts specified items for the full-year 2024 of \$1.30 per share primarily related to intangible amortization, costs associated with acquisitions, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share would be \$4.50 to \$4.70 for the full-year 2024. 6. t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.